Compass Pathways (CMPS) Q3 2026 earnings review
Compass Pathways nears FDA filing, but launch costs lift losses
Compass Pathways, the mental health drug developer, is weeks away from its final US regulatory filing while launch preparations drive its costs up. Operating losses widened 39% from a year ago to $56 million as selling and administrative spending more than doubled. Chief executive Kabir Nath kept the first-half 2027 launch target, and new share sales lifted cash to $444 million, above what prior burn rates pointed to by our math.
| Operating loss | $56.4M +39% from a year ago |
|---|---|
| Selling and administrative costs | $33.0M +150% from a year ago |
| Cash and cash equivalents | $444.0M up from $433.3M last quarter |
| Final FDA application outlook | On track filing within two weeks; launch H1 2027 |
⚖️ Verdict: 🟢 Bullish
The story got better because the company narrowed its final FDA filing window to mid-November and backed it with one-year trial data showing that an extra dose extends the drug's benefit. One caution: commercial hiring is lifting the cost base fast, and the apparent drop in headline net loss was just a non-cash accounting gain on warrants.
The question now is whether regulators and insurers clear the path fast enough to match the rising expense rate. Either the priority review and federal drug rescheduling finish smoothly for a spring 2027 launch, or regulatory and reimbursement delays leave the company burning cash into 2028. The FDA review decision in early 2027 will settle the first step.
🐂 Bull Case
FDA Application Lands in Mid-November With One-Year Data
Compass Pathways is developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression (TRD), which is depression that has not responded to at least two prior medications. Chief executive Kabir Nath said the company is "executing with urgency and discipline to launch this much needed treatment in the first half of 2027".
The biotechnology group narrowed its regulatory timeline, stating that the "Final NDA submission will be filed in the next two weeks" for its New Drug Application (NDA) with the US Food and Drug Administration (FDA). It also reported 52-week data from its COMP005 trial showing "notable added benefit from an additional COMP360 25 mg dose during Part C extending durability out to one year".
This matters because the company holds a National Priority Voucher (NPV), a regulatory award that can shorten the FDA review to one or two months. Completing the filing in mid-November puts an approval decision in early 2027, while the one-year durability data supports the case to doctors and insurers that patients need only a few treatments a year.
What to watch: FDA acceptance of the completed filing and any announcement of an advisory committee meeting in late 2026. A review without an advisory panel delay would keep the first-half 2027 commercial launch on schedule.
Clinic Network Reaches 8,500 Sites Ahead of Launch
Because COMP360 requires patients to be monitored for several hours after taking the drug, Compass needs existing psychiatric clinics to administer it. The company plans to plug its treatment into the network of US clinics that already deliver multi-hour depression treatments.
Compass reported that this network has grown to more than 8,500 treatment centers "already equipped to deliver multi-hour treatments", up 6.3% from last quarter and 41.7% from a year ago by our math. Meanwhile, the company is selecting its sales team and educating healthcare providers ahead of the planned first-half 2027 launch.
The expanding clinic base matters because it removes the need for the London-based developer to build its own treatment centers. With over 8,500 sites already operating across the United States, physical room capacity will not limit early sales once regulators clear the drug.
What to watch: the number of clinics certified under the FDA's safety program once the drug is approved in early 2027. A fast certification pace would allow the new sales force to convert existing clinic capacity into early prescriptions.
PTSD Trial Adds a Veterans Affairs Partnership
Beyond depression, Compass is testing COMP360 in post-traumatic stress disorder (PTSD), a severe psychiatric condition affecting about 13 million Americans annually where only two medications have FDA approval. Its late-stage PTSD study is underway and is designed to support regulatory approval.
This quarter, the company announced that it is working with the US Department of Veterans Affairs on a multi-site randomized controlled clinical trial. That study will test COMP360 in military veterans who have treatment-resistant depression, including patients who also suffer from PTSD.
Working directly with the Veterans Affairs health system matters because veterans face high rates of both conditions and represent a major government healthcare buyer. Generating clinical evidence inside the agency's own hospitals should help secure federal coverage if the drug wins approval.
What to watch: enrollment updates and target readout dates for the late-stage PTSD trial on upcoming quarterly calls. Clear timelines would show how soon the second disorder could add to the depression business.
🐻 Bear Case
Launch Hiring Pushes Operating Losses Up 39%
Preparing to sell a new psychiatric drug requires heavy upfront spending on sales teams, supply chains, and insurer negotiations before any revenue arrives. Compass is building this commercial organisation now while still funding its clinical trials.
The company's operating loss widened 39.2% from a year ago to $56.4 million, driven by selling, general and administrative expenses "to support our commercial preparedness activities in advance of potential FDA approval and commercialization of COMP360 for TRD". While management emphasizes disciplined execution, it issued 6.0 million more ordinary shares this quarter, which kept cash up at $444.0 million despite the wider loss.
- Selling, general and administrative expenses: $33.0 million, up 149.6% from a year ago and 42.2% from last quarter
- Commercial and administrative share of operating costs: 58.4%, up 25.8 percentage points from a year ago by our math
- Ordinary shares outstanding: 141.7 million, up 47.5% since December 2025 and 4.4% from last quarter by our math
- Diluted share count: 162.6 million, up 70.5% from a year ago by our math
This matters because the cash runway into 2028 implies quarterly spending can rise toward $74 million by our math. If clinic adoption or insurer coverage starts slowly in 2027, the higher cost base will force further share sales that dilute existing owners.
What to watch: selling, general and administrative expenses in the fourth quarter as sales reps are hired. Another 40% quarterly jump would consume the cash cushion faster than the 2028 outlook suggests.
Warrant Accounting Masks a $51 Million Quarterly Loss
Compass financed its operations in 2025 and early 2026 partly by issuing warrants, which are contracts giving investors the right to buy shares later. Accounting rules require the company to record these warrants as a liability of $296.7 million and adjust their value every quarter.
On paper, third-quarter net loss shrank 92.9% from a year ago to $9.8 million, or $0.31 per diluted share. However, that headline figure includes a $40.8 million non-cash accounting gain on the warrants, compared with a $101.3 million warrant loss a year ago.
Stripping out the warrant adjustments, the net loss was $50.6 million by our math, which is 39.1% worse than the $36.4 million loss on the same basis a year ago. Readers who look only at the headline net loss will miss that the underlying cost of running the business is rising.
What to watch: loss from operations and operating cash flow in the full third-quarter filing. Those two lines show the real cash drain without distortion from warrant accounting.
Risks this quarter didn't answer
Five standing regulatory, commercial, and financial concerns received no new data in the third-quarter press release.
- Drug Enforcement Administration (DEA) and state rescheduling: psilocybin remains a restricted drug, and only the actual post-approval scheduling calendar in 2027 will show if federal and state rules delay the launch.
- Insurance reimbursement and pricing: the company has not disclosed its target drug price or how insurers will pay clinics for six-hour monitoring sessions, which requires payer coverage updates before launch.
- Rival psilocybin programs: management gave no update on how Usona Institute's competing psilocybin trial or shorter-acting psychedelics could affect early market share, a question for the conference call.
- FDA durability standards: while Compass reported 52-week open-label data, only the FDA's review decision will confirm whether unblinded one-year data satisfies the agency's recent psychedelic guidelines.
- UK research tax credits: the third-quarter tax credit benefit fell 47.8% from a year ago to $2.0 million, and the full quarterly filing is needed to see if a dispute with UK tax authorities over $18.4 million in prior credits was resolved.
💲 Other KPIs
Cash rose 2.5% from last quarter and 138.8% from a year ago, increasing by $10.7 million since June by our math. After falling by $33 million to $38 million per quarter throughout 2025, the cash balance jumped in early 2026 on a major financing and edged higher in Q3 as ongoing share sales outpaced operating spending.
Research spending fell 14.2% from a year ago and 19.6% from last quarter, continuing a steady decline from $30.3 million in Q2 2025 and $29.2 million in Q2 2026. The mental health developer spent less on clinical trials as its late-stage depression studies wrapped up and early discovery programs were closed, freeing funds for commercial hiring.
🔮 Guidance
Unchanged. Compass still expects its $444.0 million cash pile to fund operating expenses and capital requirements into 2028. By our math, funding the business for the six quarters from September 2026 through early 2028 allows an average quarterly cash burn of up to $74 million, above the $56.4 million third-quarter operating loss. That leaves room for launch spending to rise in Q4 and 2027.
Unchanged and narrowed. Management kept its fourth-quarter target and specified that the final portion of the rolling FDA application will be filed by mid-November 2026. That maintains a three-quarter streak of holding the fourth-quarter filing target first issued in early 2026.
Unchanged. The psychedelic drug developer still plans to launch COMP360 for treatment-resistant depression in the first half of 2027, subject to FDA approval. By our math, a mid-November filing followed by a one-to-two-month priority FDA review and a 90-day federal drug rescheduling window puts commercial readiness in the second quarter of 2027.
❓ Key Questions
How much cash did share sales bring in during Q3?
Cash rose by $10.7 million to $444.0 million despite a $56.4 million operating loss, and ordinary shares increased by 6.0 million. Since the press release omits the cash flow statement, investors need to know exact quarterly operating cash burn versus financing proceeds.
What price and clinic reimbursement model will COMP360 use?
Commercial spending jumped 150% to prepare for a first-half 2027 launch, and Compass now has 52-week durability data in hand. Management still has not disclosed its target drug price or how insurers will reimburse clinics for multi-hour monitoring.
Who is leading finance after the CFO absence on calls?
No chief financial officer appeared on the company's 2026executive lists or spoke on recent earnings calls. With quarterly operating expenses climbing toward commercial launch levels, investors need clarity on permanent financial leadership.
When will the late-stage PTSD trial finish enrolling patients?
Compass highlighted its ongoing late-stage PTSD trial and a new clinical trial partnership with the Department of Veterans Affairs, but gave no patient enrollment numbers or target readout dates for either study.